MicroRNA as a Therapeutic Target in Cardiac Remodeling

Chao Chen1, Murugavel Ponnusamy1, Cuiyun Liu1

  • 1Center for Developmental Cardiology, Institute for Translational Medicine, Qingdao University, Dengzhou Road 38, Qingdao 266021, China.

Insights

Altered microRNA (miRNA) expression significantly impacts heart disease development. This review explores how miRNAs regulate myocardial remodeling, affecting cardiac hypertrophy, injury, fibrosis, and inflammation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiovascular Research

Background:

  • MicroRNAs (miRNAs) are small RNA molecules (18-25 nucleotides) involved in gene regulation.
  • Dysregulated miRNA expression is implicated in various diseases, particularly heart diseases.
  • Myocardial remodeling, a pathological consequence of heart diseases, involves complex cellular changes.

Purpose of the Study:

  • To review the critical role of microRNAs in regulating myocardial remodeling.
  • To elucidate how miRNAs modulate cardiac hypertrophy, cardiomyocyte injury, fibrosis, angiogenesis, and inflammation.
  • To identify miRNA targets that influence cardiac remodeling processes.

Main Methods:

  • Literature review of studies investigating microRNA expression and function in cardiac diseases.
  • Analysis of mechanisms by which miRNAs regulate key aspects of myocardial remodeling.
  • Identification and categorization of miRNA targets within cardiac tissues.

Main Results:

  • miRNAs are central regulators of myocardial remodeling, influencing cardiac hypertrophy, cardiomyocyte injury, fibrosis, angiogenesis, and inflammation.
  • Aberrant miRNA expression can lead to detrimental effects on cardiac function.
  • Specific miRNAs target receptors, signaling molecules, and transcription factors to modulate remodeling.

Conclusions:

  • Maintaining balanced miRNA expression is crucial for cardiac functional recovery after injury.
  • Understanding miRNA roles and targets offers potential therapeutic strategies for heart diseases.
  • miRNAs represent key players in the pathogenesis and potential treatment of myocardial remodeling.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K